Investigating the Role of Polarity Regulators in Pancreatic Ductal Adenocarcinoma (PDAC) Pathogenesis and Therapy.
- Supervisors: Dr Pedro Perez-Mancera Prof William Greenhalf
Description
Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies, with a five-year survival rate of ~10%. The lack of effective therapeutic options and the high incidence of chemoresistance underscore the urgent need to elucidate the molecular mechanisms driving PDAC development and progression.
Loss of cell polarity, a hallmark of epithelial neoplasia development, is critical during the progression from pancreatic preinvasive lesions to invasive PDAC. Altered expression of cell polarity regulators leads to dysregulation of oncogenic and tumour suppressive pathways, thereby promoting tumour progression. Further evidence indicates that inactivation of polarity genes drives resistance to chemotherapy and correlates with poor outcomes.
Emerging evidence, including work from our group and others, has demonstrated that mutations in polarity regulators are relevant genetic events in PDAC development. These findings highlight the need to investigate the tumour suppressive functions of polarity genes in PDAC and their clinical potential to identify novel strategies for patient stratification and therapeutic intervention.
Hypothesis: A better understanding of polarity signalling during PDAC development will reveal predictive biomarkers of drug response and molecular targets for therapeutic intervention in PDAC.
Aim and experimental strategy
This interdisciplinary project integrates genetic, pharmacological and clinical approaches to investigate the biological and therapeutic relevance of polarity regulators in PDAC.
1.- Molecular (viral-mediated shRNA/CRISPR) and cellular biology (2D/3D cell cultures) approaches will be employed to assess the tumour suppressive activities of polarity regulators in PDAC cells.
2.- Pharmacological and transcriptomic approaches will be used to identify molecular pathways associated with drug response.
3.- Clinical relevance of the findings will be evaluated in a collection of human PDAC samples.
Impact
This project introduces an innovative and comprehensive strategy designed to address critical unmet needs in PDAC research, with a strong focus on achieving meaningful translational impact. By targeting polarity regulators, we aim to uncover novel therapeutic targets and predictive biomarkers, ultimately striving to significantly improve clinical outcomes for PDAC patients.
Training
This PhD project will provide training in cancer biology and will offer a framework to develop their skills in molecular and cellular biology. Work will be undertaken in collaboration with members of the Pancreatic Group in Liverpool, including basic and clinical researchers. The student’s project will synergise with other research aiming at addressing critical gaps in PDAC pathogenesis and therapy.
Application process
The project is suited to a student with at least a good B.Sc. Upper Second in Cancer Biology, Biological Sciences, or related subjects, and evidence of lab experience. Applications should be made via CV and cover letter, sent to Dr Perez-Mancera (pedro.perez-mancera@liverpool.ac.uk) Applications will be reviewed until a suitable candidate is appointed. This is a self-funded project.
Availability
Open to students worldwide
Funding information
Funded studentship
The project is open to both European/UK and International students. It is UNFUNDED and applicants are encouraged to contact the Principal Supervisor directly to discuss their application and the project.
Assistance will be given to those who are applying to international funding schemes.
The successful applicant will be expected to provide the funding for tuition fees and living expenses as well as research costs of £12,000 per annunm.
New self-funded applicants may be eligible for a tuition fees bursary.
Details of costs can be found on the University website:
https://www.liverpool.ac.uk/study/postgraduate-research/fees-and-funding/fees-and-costs/
Supervisors
References
Bermejo-Rodriguez C et al., Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Cancer Res. 2024 Sep 16;84(18):2968-2984. doi: 10.1158/0008-5472.CAN-23-3419.
- Greenhalf W et al., Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014 Jan;106(1):djt347. doi: 10.1093/jnci/djt347.
- Pérez-Mancera PA et al., The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 2012 Apr 29;486(7402):266-70. doi: 10.1038/nature11114.